BrightEdge HAS INVESTED in 18 COMPANIES with the POTENTIAL to IMPACT 1.5M+ PATIENTS* and THEIR FAMILIES IN THE FIGHT AGAINST CANCER

BY THE NUMBERS

ACS Impact Venture Fund $78M GROSS ASSET VALUE

$28.9M RAISED by portfolio companies to advance PATIENT-CENTRIC INNOVATIONS such as therapeutics, diagnostics, devices and other technologies

$9.7M IN GAINS ON $28.9M IN INVESTMENTS

4 NEW INVESTMENTS and 6 FOLLOW-ON INVESTMENTS ACROSS 5 PORTFOLIO COMPANIES

DEFINING IMPACT AND INNOVATION BY:

Partnering with ACS** Discovery Research to narrow the gap between scientific grantmaking and equity investments.

Identifying and enabling the next generation of cancer-fighting entrepreneurs and leaders.

Mobilizing collaborator networks to accelerate and deepen impact of investments.

BrightEdge, LLC is the American Cancer Society’s innovation and impact investing arm. To learn more about BrightEdge and read the 2022 Annual Report, visit acsbrightedge.org.

*Cancer Impact Investment Framework™ is a proprietary and unique framework that assesses investment impact across American Cancer Society mission priority areas and cancer care continuum

**The American Cancer Society is the leading cancer-fighting organization with a vision of ending cancer as we know it, for everyone. To learn more about ACS, visit cancer.org